Emergent BioSolutions Inc. (NYSE:EBS) announces that it has completed the sale of its Baltimore-Bayview drug substance manufacturing facility to Syngene International. Emergent received approximately $36.5 million at closing, which is subject to customary post-closing adjustments. Pursuant to the sale, Syngene acquired the assets and equipment associated with the Baltimore-Bayview facility. In addition, Emergent retains the rights to secure manufacturing services and capacity at the facility for future growth and pandemic response production in collaboration with Syngene.
Read the full article: Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International //
Source: https://www.globenewswire.com/news-release/2025/03/19/3045818/33240/en/Emergent-BioSolutions-Finalizes-Sale-of-Baltimore-Bayview-Manufacturing-Site-to-Syngene-International.html